Effectiveness, Sex Differences, and Patient Experience in Real-World Use of Long-Acting Cabotegravir and Rilpivirine: Results from a Prospective Study Authors: Ana González-Cordón, Júlia Calvo, Leire Berrocal, Maite León-Fabo, Maria Martínez-Rebollar, Ivan Chivite, Alexy Inciarte, Paula Arreba, Juan Ambrosioni, Lorena de la Mora, Pilar Callau, Alberto Foncillas, Abiu Sempere, José Luis Blanco, Esteban Martinez, Jose M. Miro, Roger Llobet, Elisa de Lazzari, Josep Mallolas, Montserrat Laguno, Berta Torres Published: 2026 ABSTRACT IntroductionLong-acting intramuscular cabotegravir plus rilpivirine (LA-CAB/RPV) administered every 2 months (Q2M) has been available in Spain since January 2023 as a switch strategy for HIV treatment. We evaluated characteristics, effectiveness, tolerability, and acceptance, including patient-reported outcomes, stratified by sex in people with HIV switching to LA-CAB/RPV.MethodsObservational, prospective, cohort study in Hospital Clínic of Barcelona, Spain. Participant characteristics according to sex at birth and treatment effectiveness [HIV-RNA < 50 copies/mL by on treatment (OT), modified intention-to-treat (mITT), and intention to-treat (ITT) analyses] were evaluated. Self-administered electronic questionnaires were collected.ResultsFrom February 2023 to February 2025, 57/741 (8%) women and 684/741 (92%) men started LA-CAB/RPV, compared to 816/5901 (14%) women that continued with other antiretroviral therapy (ART) (p < 0.001) in our cohort. Women were older, had longer time since HIV diagnosis and on ART, lower nadir CD4, and were more frequently Spanish-born than men.Effectiveness by OT, mITT, and ITT in the 461 participants (29 women and 432 men) who reached week 52 of follow-up was 96%, 83%, and 83% and 99%, 92%, and 89%, respectively, without significant differences. There were 8 (1.7%) confirmed virological failures and 40 (9%) discontinuations with no significant differences by sex. Acceptance, tolerability of injections, and HIV medication burden globally improved during follow-up. Women reported more medication burden and disclosure worries than men.ConclusionsCompared to our general cohort, proportionally fewer women than men switched to LA-CAB/RPV. Effectiveness, adherence, tolerability, and acceptance were high without significant differences by sex. In this study, women expressed more frequent disclosure issues and showed significantly different baseline characteristics compared to men, highlighting the importance of sex-disaggregated data analysis. These results should be confirmed in larger studies.Supplementary InformationThe online version contains supplementary material available at 10.1007/s40121-026-01373-w. Key Summary Points Why carry out this study?Real-world, sex-stratified data in people with HIV switching to long-acting cabotegravir-rilpivirine (LA-CAB/RPV) are limited.We report characteristics, effectiveness, tolerability, and acceptance, including patient-reported outcomes, stratified by sex in people switching to LA-CAB/RPV.What was learned from the study?In a cohort of 741 people switching to LA-CAB/RPV, women were underrepresented, compared with our general cohort.Effectiveness, adherence, tolerability, and acceptance were uniformly high across sexes, though women reported more disclosure challenges.Our findings highlight the importance of sex-disaggregated data in understanding the differential characteristics, needs, and concerns of people with HIV. Why carry out this study?Real-world, sex-stratified data in people with HIV switching to long-acting cabotegravir-rilpivirine (LA-CAB/RPV) are limited.We report characteristics, effectiveness, tolerability, and acceptance, including patient-reported outcomes, stratified by sex in people switching to LA-CAB/RPV.What was learned from the study?In a cohort of 741 people switching to LA-CAB/RPV, women were underrepresented, compared with our general cohort.Effectiveness, adherence, tolerability, and acceptance were uniformly high across sexes, though women reported more disclosure challenges.Our findings highlight the importance of sex-disaggregated data in understanding the differential characteristics, needs, and concerns of people with HIV. Introduction The combination of long-acting cabotegravir-rilpivirine (LA-CAB/RPV) is the first available injectable antiretroviral regimen approved for maintenance therapy, representing a new paradigm in the history of antiretroviral therapy (ART). Data from the pivotal phase 3 studies demonstrated high efficacy and non-inferiority compared to standard oral regimens [1–3]. These findings have been further corroborated by real-world evidence from observational cohorts [4–6]. Although some efficacy data disaggregated by sex at birth has been reported [1, 2], most outcomes including efficacy, tolerability, and patient experience were reported overall. Few studies have reported virologic outcomes and adverse effects by sex [7–10]. Overlooking these differences and not stratifying the data by sex contributes to biases in the understanding of the tolerance and efficacy of antiretroviral treatment studies in both sexes. Women have historically had poorer treatment efficacy outcomes compared to men living with HIV, likely due to sex-related differences, such as an increased occurrence of adverse effects, as well as gender-related factors [11]. Patient-reported outcomes (PROs) are essential for evaluating real-world impact, as they capture differences in symptoms burden, side effects, and daily functioning that clinical trials may overlook. PROs are consistently favorable to LA-CAB/RPV therapy in both clinical trials and real-world settings. Across pivotal studies (FLAIR, ATLAS, ATLAS-2 M), patients reported greater treatment satisfaction, and strong preference for injectable therapy over daily oral regimens, as measured by validated tools as the HIV Treatment Satisfaction (HIVTSQ) and the ACCEPT questionnaire [2, 12, 13]. The SOLAR phase 3b study confirmed improvements in treatment satisfaction and psychological well-being [14]. However, no overall significant impact on validated quality of life questionnaires has been observed in clinical trials [2, 12, 13]. We conducted a prospective observational study including all people with HIV who switched to LA-CAB/RPV administered every 2 months (Q2M) and accepted to participate. This study evaluated effectiveness, tolerability, and acceptance, including PROs with a focus on sex-based characteristics and stratified outcomes in people with HIV switching to LA-CAB/RPV in Hospital Clínic of Barcelona, Spain. Methods This article was written following Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations. Design, Setting, and Study Population People with HIV initiating LA-CAB/RPV at the HIV Unit of Hospital Clínic of Barcelona were invited to participate in an observational, prospective, cohort, single-center study. Switching to LA‑CAB/RPV was offered on an individual basis, either proposed by the clinician or requested by the patient. All people who switched to LA-CAB/RPV in routine clinical practice were included, regardless of the presence of any contraindications according to the product label at baseline. Clinical information was routinely collected, and HIV RNA testing was done at weeks 12, 28, and 52 and every 24 weeks thereafter, and whenever deemed necessary by the treating physician. We used “men” and “women” to refer to participants classified as male and female at birth, unless otherwise specified. Patient-Reported Outcomes Participants enrolled during the first year were invited to answer self-administered electronic questionnaires. Several PRO instruments (Table S1) were included at pre-specified timepoints to assess quality of life, tolerability, and acceptability of injections, treatment satisfaction, acceptance, and preference. A single question regarding reason for treatment switch was included at baseline to explore why participants elected to switch to long-acting treatment. The overall benefit–risk balance of the treatment from the patient’s perspective was assessed using the general acceptance dimension of the ACCEPT questionnaire [12, 15]. The acceptability and tolerability of injections and injection site reactions (ISRs) were evaluated using the Perception of Injection (PIN) questionnaire, developed by modifying the Vaccinees’ Perception of Injection questionnaire for gluteal IM injections and validated in a population of people with HIV [16]. A score for pain-intensity assessment by visual analogue scale was also included (range 0–10). To assess participant treatment preference, a single-item question evaluating treatment preference, along with questions evaluating attributes supporting this preference, was included at week 52. The HIV/AIDS-Targeted Quality of Life (HAT-QoL) Questionnaire for Evaluation of Health-related Quality of Life in People Living with HIV/AIDS was used. Three dimensions were included: life satisfaction domain, medication concerns domain, and disclosure worries domain [17, 18]. Outcomes Baseline characteristics of participants starting LA-CAB/RPV were analyzed and stratified by sex at birth and then compared with the characteristics of people continuing with other ARTs at our center. Follow-up analysis included people with a potential follow-up of at least 52 weeks at the time of database closure (February 2025). Treatment effectiveness was evaluated by the percentage of people with HIV-RNA < 50 copies/mL by three analytic strategies that describe different assumptions regarding treatment discontinuation and missing data: on treatment (OT), discontinuation and missing excluded; modified intention-to-treat (mITT), discontinuation equal failure and missing excluded; and intention to-treat (ITT), discontinuation and missing equal failure. Confirmed virological failure (CVF) was defined as two consecutive viral loads (VLs) above 50 copies/mL. Subsequently, the definitions proposed by the CONSENSUS-LAI Study were also incorporated [19]. Participants responses to questionnaires were evaluated at baseline and 12, 28, and 52 weeks. All results were stratified and analyzed focusing on sex at birth-based differences. Data Collection An electronic case report form (eCRF) was developed in the REDCap system [20, 21] hosted at the Hospital Clínic of Barcelona. It was specifically designed for the study to administer electronic questionnaires and collect clinical variables, except for routine laboratory parameters and sociodemographic characteristics, which were retrieved from the electronic medical record system of the HIV Unit. Statistical Analysis Categorical variables were described using absolute and relative frequencies. Continuous variables were summarized using median and interquartile range (IQR), or mean and standard deviation (SD). Comparisons between categorical variables were performed using the χ2 test or Fisher’s exact test, and continuous variables were compared between groups using the Mann–Whitney U test or Student’s t test, as appropriate. The ACCEPT questionnaire responses were assessed by Poisson regression models with robust standard errors, comparing the response “totally convinced” versus all the other responses, omitting the response “I don’t know”. VAS scale evolution was analyzed by mixed effects linear regression, and the PIN questionnaire questions were assessed by Poisson regression models with robust standard errors, comparing the responses “totally acceptable/very acceptable” vs. “moderately acceptable/a little acceptable/not at all acceptable”. For the HAT-QoL questionnaire, the dimension scores were computed by summing the responses to all items within a dimension (scored or rescored in a positive direction) and converting the sums to a 0–100 scale, whereby higher scores indicated better function and well-being. Mixed effects linear regression models were used to analyze the evolution of well-being for each dimension during follow-up. To see more specific changes inside each dimension, the responses for each question were grouped into two categories: the two responses associated with better well-being versus the three responses associated with worse well-being. To assess these differences for each question, Poisson regression models with robust standard errors were used. The estimated effect sizes from the Poisson regressions were reported as risk ratio (RRs) with their corresponding confidence intervals (CIs). Missing PROs data were not imputed; analyses were performed using observed responses only. All results were stratified and analyzed focusing on sex at birth-based differences. The study was not powered a priori to detect formal sex at birth-based differences in effectiveness; therefore, these stratified analyses were conducted for descriptive purposes and should be considered hypothesis-generating. All statistical tests were two-tailed, and the significance level was set at 5%. Data management and statistical analyzes were performed using Stata version 18 [22]. Ethical Approval The protocol was approved by the local Ethics Committee (protocol number HCB/2022/0770) and was conducted in accordance with the Good Clinical Practice Guidelines and Declaration of Helsinki. All participants provided written informed consent before enrolment. Results From 2 February 2023 to 13 February 2025, 770 people started LA-CAB/RPV at the HIV Unit of Hospital Clínic, accounting for 11% of total cohort of people with HIV followed at this unit, and 741 (96%) accepted to participate in the observational study: 57 (8%) women and 684 (92%) men at birth, compared to 816 (14%) women and 5085 (86%) men that continued with other ART (p < 0.001). Baseline Characteristics We compared baseline characteristics for women and men, both in LA-CAB/RPV cohort and in those people continuing on other antiretroviral treatments (O-ART) in the general cohort in our unit (Tables 1 and 2). Among participants who switched to LA-CAB/RPV, women were older [median age 52 (IQR 41–58) years in women vs. 43 (IQR 35–51) in men, p < 0.001], had longer time since HIV diagnosis (22 (IQR 14–28) vs. 11 (IQR 7–17) years p < 0.001), longer time on ART (15 (IQR 7–22) vs. 8 (IQR 2–13) years; p < 0.001), had lower nadir CD4 (IQR 243 (139–393) vs. 372 (IQR 245–511); p < 0.001) but similar last CD4 count before switch (785 (IQR 533–934) vs. 719 (IQR 568–930); p = 0.559), and were more frequently Spanish-born than men (61% vs. 43%; p = 0.007) (Table 1). Sexual transmission was the most frequent mode of HIV acquisition in both groups, although a higher percentage of intravenous drug use was reported as a mode of transmission in women (16% vs. 4%; p < 0.001). The same differences were observed in the cohort of people that did not switch to LA-CAB/RPV (O-ART) (Table 2). Table 1Baseline characteristics of participants by sex at birth (LA-CAB/RPV group)Women (Female at birth)(n = 57)Men (Male at birth)(n = 684)Total(n = 741)pAge, median (IQR)52 (41–58)43 (35–51)43 (35–52)< 0.001Gender, men, n (%)0 (0%)678 (99%)678 (91%)< 0.001Gender, women, n (%)57 (100%)6 (1%)63 (9%)Origin, n (%) Spain35 (61%)292 (43%)327 (44%)0.007 Other European countries2 (4%)83 (12%)85 (11%) Latin America17 (30%)277 (40%)294 (40%) Other3 (5%)32 (5%)35 (5%)Mode of HIV acquisition, n (%) MSM0 (0%)606 (89%)606 (83%)< 0.001 Heterosexual39 (70%)33 (5%)72 (10%) IDU9 (16%)27 (4%)36 (5%) Vertical5 (9%)2 (0%)7 (1%)BMI ≥ 30 kg/m2, n (%)12 (21%)61 (9%)73 (10%)0.003Years since diagnosis, median (IQR)22 (14–28)11 (7–17)12 (7–18)< 0.001Undetectable VL (< 50 copies/mL), n (%)52 (91%)677 (99%)729 (98%)0.001Time with VL < 50 copies/mL, median years (IQR)11 (5–17)7 (2–12)7 (2–12)< 0.001Last CD4, cells/μL, median (IQR)785 (533–934)719 (568–930)723 (568–933)0.559Nadir CD4, cells/μL, median (IQR)243 (139–393)372 (245–511)363 (234–504)< 0.001Historic subtype available, n (%)a22 (39%)260 (38%)282 (38%)1.000 Subtype A1 (5%)7 (3%)8 (3%)0.407 Subtype B13 (59%)184 (70%)197 (70%) Subtype B + Other/s4 (18%)43 (17%)47 (17%) Other4 (18%)26 (10%)30 (11%)Historic genotype available, n (%)a26 (46%)318 (46%)344 (46%)0.898 Any mutation present5 (19%)45 (14%)50 (14%)0.560 NNRTI mutations1 (4%)22 (7%)23 (6%)1.000 INSTI mutations0 (0%)4 (1%)4 (1%)1.000Years in ART, median (IQR)15 (7–22)8 (2–13)8 (2–14)< 0.001Number of previous ARTs, median (IQR)5 (3–9)2 (1–5)3 (1–5)< 0.001Previous ART II based35 (62%)470 (71%)505 (70%)0.158 NNRTI based5 (9%)76 (11%)81 (11%) PI based7 (12%)39 (6%)46 (6%) Other combinations9 (16%)77 (12%)86 (12%)Previous virological failure21 (37%)72 (11%)93 (13%)< 0.001Oral lead-in phase (OLI)4 (7%)19 (3%)23 (3%)0.093IQR interquartile range, MSM men who have sex with men, IDU injection drug user, VL viral load, BMI body mass index, NNRTI non-nucleoside reverse transcriptase inhibitors, ART antiretroviral therapy, II integrase inhibitors, PI protease inhibitorsaDetails on viral subtype and previous mutations in Supplemental MaterialTable 2Baseline characteristics of participants by sex at birth (O-ART group)Women (Female at birth)(n = 816)Men (Male at birth)(n = 5085)Total(n = 5901)pAge, median (IQR)57 (49–63)47 (38–58)49 (39–59)< 0.001Gender, men, n (%)3 (0%)4974 (98%)4977 (84%)< 0.001Gender, women, n (%)813 (100%)106 (2%)919 (16%)Origin, n (%) Spain578 (71%)2117 (42%)2695 (46%)< 0.001 Other European countries43 (5%)469 (9%)512 (9%) Latin America138 (17%)1978 (39%)2116 (36%) Other57 (7%)521 (10%)578 (10%)Mode of HIV acquisition, n (%) MSM0 (0%)3994 (79%)3994 (68%)< 0.001 Heterosexual623 (76%)535 (11%)1158 (20%) IDU137 (17%)336 (7%)473 (8%) Vertical23 (3%)18 (0%)41 (0%) Other33 (4%)202 (4%)235 (4%)BMI ≥ 30 kg/m2, n (%)77 (18%)274 (8%)351 (9%)< 0.001Years since diagnosis, median (IQR)26 (17–32)14 (8–22)15 (9–25)< 0.001Undetectable VL (< 50 copies/mL), n (%)752 (92%)4680 (92%)5432 (92%)0.905Time with VL < 50 copies/mL, median years (IQR)14 (6–18)7 (3–14)8 (3–14)< 0.001Last CD4, cells/μL, median (IQR)699 (515–936)724 (537–937)720 (534–937)0.246Nadir CD4, cells/μL, median (IQR)207 (99–313)318 (179–476)298 (164–459)< 0.001Historic subtype available, n (%)294 (37%)2193 (43%)2487 (42%)< 0.001 Subtype A9 (3%)55 (3%)64 (3%)0.136 Subtype B192 (65%)1469 (67%)1661 (67%) Subtype B + Other/s46 (16%)411 (19%)457 (18%) Other47 (16%)258 (12%)305 (12%)Historic genotype available, n (%)447 (55%)2746 (54%)3193 (54%)0.679 Any mutation present221 (49%)963 (35%)1184 (37%)< 0.001 NNRTI mutations148 (33%)666 (24%)814 (26%)< 0.001 INSTI mutations37 (8%)130 (5%)167 (5%)0.002Years in ART, median (IQR)22 (12–28)10 (4–18)11 (4–20)< 0.001Number of previous ARTs, median (IQR)6 (4–10)3 (1–5)3 (1–6)< 0.001Previous ART II based509 (62%)3678 (72%)4187 (71%)< 0.001 NNRTI based102 (12%)470 (9%)572 (10%) PI based119 (15%)534 (11%)653 (11%) Other combinations86 (11%)403 (8%)489 (8%)Previous virological failure375 (46%)1149 (23%)1524 (26%)< 0.001IQR interquartile range, MSM men who have sex with men, IDU injection drug user, VL viral load, BMI body mass index, NNRTI non-nucleoside reverse transcriptase inhibitors, ART antiretroviral therapy, II integrase inhibitors, PI protease inhibitors, O-ART group people continuing on other antiretroviral treatments Table 1Baseline characteristics of participants by sex at birth (LA-CAB/RPV group)Women (Female at birth)(n = 57)Men (Male at birth)(n = 684)Total(n = 741)pAge, median (IQR)52 (41–58)43 (35–51)43 (35–52)< 0.001Gender, men, n (%)0 (0%)678 (99%)678 (91%)< 0.001Gender, women, n (%)57 (100%)6 (1%)63 (9%)Origin, n (%) Spain35 (61%)292 (43%)327 (44%)0.007 Other European countries2 (4%)83 (12%)85 (11%) Latin America17 (30%)277 (40%)294 (40%) Other3 (5%)32 (5%)35 (5%)Mode of HIV acquisition, n (%) MSM0 (0%)606 (89%)606 (83%)< 0.001 Heterosexual39 (70%)33 (5%)72 (10%) IDU9 (16%)27 (4%)36 (5%) Vertical5 (9%)2 (0%)7 (1%)BMI ≥ 30 kg/m2, n (%)12 (21%)61 (9%)73 (10%)0.003Years since diagnosis, median (IQR)22 (14–28)11 (7–17)12 (7–18)< 0.001Undetectable VL (< 50 copies/mL), n (%)52 (91%)677 (99%)729 (98%)0.001Time with VL < 50 copies/mL, median years (IQR)11 (5–17)7 (2–12)7 (2–12)< 0.001Last CD4, cells/μL, median (IQR)785 (533–934)719 (568–930)723 (568–933)0.559Nadir CD4, cells/μL, median (IQR)243 (139–393)372 (245–511)363 (234–504)< 0.001Historic subtype available, n (%)a22 (39%)260 (38%)282 (38%)1.000 Subtype A1 (5%)7 (3%)8 (3%)0.407 Subtype B13 (59%)184 (70%)197 (70%) Subtype B + Other/s4 (18%)43 (17%)47 (17%) Other4 (18%)26 (10%)30 (11%)Historic genotype available, n (%)a26 (46%)318 (46%)344 (46%)0.898 Any mutation present5 (19%)45 (14%)50 (14%)0.560 NNRTI mutations1 (4%)22 (7%)23 (6%)1.000 INSTI mutations0 (0%)4 (1%)4 (1%)1.000Years in ART, median (IQR)15 (7–22)8 (2–13)8 (2–14)< 0.001Number of previous ARTs, median (IQR)5 (3–9)2 (1–5)3 (1–5)< 0.001Previous ART II based35 (62%)470 (71%)505 (70%)0.158 NNRTI based5 (9%)76 (11%)81 (11%) PI based7 (12%)39 (6%)46 (6%) Other combinations9 (16%)77 (12%)86 (12%)Previous virological failure21 (37%)72 (11%)93 (13%)< 0.001Oral lead-in phase (OLI)4 (7%)19 (3%)23 (3%)0.093IQR interquartile range, MSM men who have sex with men, IDU injection drug user, VL viral load, BMI body mass index, NNRTI non-nucleoside reverse transcriptase inhibitors, ART antiretroviral therapy, II integrase inhibitors, PI protease inhibitorsaDetails on viral subtype and previous mutations in Supplemental Material Baseline characteristics of participants by sex at birth (LA-CAB/RPV group) IQR interquartile range, MSM men who have sex with men, IDU injection drug user, VL viral load, BMI body mass index, NNRTI non-nucleoside reverse transcriptase inhibitors, ART antiretroviral therapy, II integrase inhibitors, PI protease inhibitors aDetails on viral subtype and previous mutations in Supplemental Material Table 2Baseline characteristics of participants by sex at birth (O-ART group)Women (Female at birth)(n = 816)Men (Male at birth)(n = 5085)Total(n = 5901)pAge, median (IQR)57 (49–63)47 (38–58)49 (39–59)< 0.001Gender, men, n (%)3 (0%)4974 (98%)4977 (84%)< 0.001Gender, women, n (%)813 (100%)106 (2%)919 (16%)Origin, n (%) Spain578 (71%)2117 (42%)2695 (46%)< 0.001 Other European countries43 (5%)469 (9%)512 (9%) Latin America138 (17%)1978 (39%)2116 (36%) Other57 (7%)521 (10%)578 (10%)Mode of HIV acquisition, n (%) MSM0 (0%)3994 (79%)3994 (68%)< 0.001 Heterosexual623 (76%)535 (11%)1158 (20%) IDU137 (17%)336 (7%)473 (8%) Vertical23 (3%)18 (0%)41 (0%) Other33 (4%)202 (4%)235 (4%)BMI ≥ 30 kg/m2, n (%)77 (18%)274 (8%)351 (9%)< 0.001Years since diagnosis, median (IQR)26 (17–32)14 (8–22)15 (9–25)< 0.001Undetectable VL (< 50 copies/mL), n (%)752 (92%)4680 (92%)5432 (92%)0.905Time with VL < 50 copies/mL, median years (IQR)14 (6–18)7 (3–14)8 (3–14)< 0.001Last CD4, cells/μL, median (IQR)699 (515–936)724 (537–937)720 (534–937)0.246Nadir CD4, cells/μL, median (IQR)207 (99–313)318 (179–476)298 (164–459)< 0.001Historic subtype available, n (%)294 (37%)2193 (43%)2487 (42%)< 0.001 Subtype A9 (3%)55 (3%)64 (3%)0.136 Subtype B192 (65%)1469 (67%)1661 (67%) Subtype B + Other/s46 (16%)411 (19%)457 (18%) Other47 (16%)258 (12%)305 (12%)Historic genotype available, n (%)447 (55%)2746 (54%)3193 (54%)0.679 Any mutation present221 (49%)963 (35%)1184 (37%)< 0.001 NNRTI mutations148 (33%)666 (24%)814 (26%)< 0.001 INSTI mutations37 (8%)130 (5%)167 (5%)0.002Years in ART, median (IQR)22 (12–28)10 (4–18)11 (4–20)< 0.001Number of previous ARTs, median (IQR)6 (4–10)3 (1–5)3 (1–6)< 0.001Previous ART II based509 (62%)3678 (72%)4187 (71%)< 0.001 NNRTI based102 (12%)470 (9%)572 (10%) PI based119 (15%)534 (11%)653 (11%) Other combinations86 (11%)403 (8%)489 (8%)Previous virological failure375 (46%)1149 (23%)1524 (26%)< 0.001IQR interquartile range, MSM men who have sex with men, IDU injection drug user, VL viral load, BMI body mass index, NNRTI non-nucleoside reverse transcriptase inhibitors, ART antiretroviral therapy, II integrase inhibitors, PI protease inhibitors, O-ART group people continuing on other antiretroviral treatments Baseline characteristics of participants by sex at birth (O-ART group) IQR interquartile range, MSM men who have sex with men, IDU injection drug user, VL viral load, BMI body mass index, NNRTI non-nucleoside reverse transcriptase inhibitors, ART antiretroviral therapy, II integrase inhibitors, PI protease inhibitors, O-ART group people continuing on other antiretroviral treatments In the LA-CAB/RPV cohort, women had more previous virological failures than men (37% vs. 11%, p < 0.001) but no differences in number of historical mutations (21% vs. 14%, p = 0.265). However, in the O-ART cohort, women had both more previous virological failures (46% vs. 23%, p < 0.001) and showed more historical mutations than men (48% vs. 35%, p < 0.001). Baseline median body mass index (BMI) in the LA-CAB/RPV cohort was similar across sexes (women 23.9 kg/m2 and men 24.9 kg/m2; p = 0.132), but proportionally more women than men had BMI ≥ 30 kg/m2 (21% vs. 9%, p = 0.003). Most of the participants, 729/741 (98%), were virologically suppressed (VL < 50 copies/ml) before LA-CAB/RPV switch, although in 12 participants (2%), LA treatment was started with detectable VL (7 (1%) men and 5 (9%) women; p = 0.001) with a median of 1207 (IQR 81–121,800) copies/mL. Basal hepatitis B virus (HBV) serological profiles are summarized in Supplementary Table S3. A total of 619/741 (84%) participants had anti-HBs positive, 165 (25%) of them had also positive anti-HBc, due to past hepatitis B infection, 19 (3%) had isolated anti-HBc, and 90 (12%) had entirely negative HBV serology at baseline (HBsAg, anti-HBc, and anti-HBs negative). Heterogeneous distribution of profiles was noted between women and men (p = 0.002). Four male participants presented a positive hepatitis B surface antigen, indicating chronic hepatitis B infections. They were mistakenly switched to LA-CAB/RPV, and subsequently returned to oral ART [23]. Antibodies for hepatitis C virus (HCV) were positive in a total of 114 patients (101 male, 13 female) but positive HCV RNA was only detected in four male patients at baseline. Follow-up at 52 Weeks Effectiveness We analyzed prospective outcomes in the 461 participants who reached week 52 of follow-up, 29 women and 432 men. Effectiveness, n/N (%, 95% CI), by OT, mITT, and ITT analysis was 24/25 (96%, 80–100), 24/29 (83%, 64–94), and 24/29 (83%, 64–94) in women and 384/389 (99%, 97–100), 384/416 (92%, 89–95), and 384/432 (89%, 86–92) in men, with no significant differences between groups (Fig. 1). There were 8 out of 461 participants (1.7%) with CVF, all in men. Three of the CFV had at least one VL above 200 copies/mL and the other five had low level viremias. Three of them changed treatment to protease inhibitor-based regimens and five resuppressed without treatment changes. If we consider the definitions proposed by the CONSENSUS-LAI Study, only one of these participants met the criteria for virological failure. This participant, along with two additional individuals, met CONSENSUS-LAI criterion (b), defined as a single VL of more than 1000 copies/mL; two of them resuppressed without changing treatment, while one switched to a protease inhibitor-based regimen.Fig. 1Treatment effectiveness at week 52. Treatment effectiveness by sex at birth evaluating the percentage of people with HIV-RNA < 50 copies/mL by on treatment (OT), modified intention-to-treat (mITT), discontinuation equal failure and missing excluded, and intention to-treat (ITT), discontinuation and missing equal failure, analyses Treatment effectiveness at week 52. Treatment effectiveness by sex at birth evaluating the percentage of people with HIV-RNA < 50 copies/mL by on treatment (OT), modified intention-to-treat (mITT), discontinuation equal failure and missing excluded, and intention to-treat (ITT), discontinuation and missing equal failure, analyses Among the eight participants with CVF as per protocol, all but one (BMI 46 kg/m2) had a BMI lower than 30 kg/m2, and all but one (with a 2-week delay) had received all injections within the window period. Five (63%) had a historical genotype prior to the switch to LA-CAB/RPV available, and none showed resistance mutations. Genotypic resistance test at the time of failure was available for four participants. One participant with high VL at failure developed NNRTI-associated mutations (K101P) and INSTI-associated mutations (G140S and Q148H), conferring high-level resistance to both drug classes. Another three participants underwent genotypic resistance testing by ultra-deep sequencing of HIV-1 DNA in peripheral blood mononuclear cells [24] as a result of VL between 50 and 200 copies/mL at the time of resistance test: all three showed mutations in both NNRTI and INSTI. However, most of the mutations detected could be APOBEC-induced, making interpretation difficult. The other four participants did not have a genotypic resistance test performed, all had VL under 100 copies/mL. Viral subtype was available for six of the eight CVF (75%), either from previous genotyping or from testing performed at the time of failure. Five had subtype B and one had subtype D. Injections were administered on time in 96% among women and 95% among men, and 3% of administrations were delayed in both groups, with no differences (p = 0.560). Seventy-nine and 80% of women and men, respectively, received all injections on time, with no differences between groups (p = 0.909). By week 52, 40 (9%) participants discontinued LA-CAB/RPV, 5/29 (17%) women and 35/432 (8%) men (p = 0.095). The reasons for ART change in women were 0 virological failure, 2 (40%) potential treatment-related adverse events (TRAEs), 1 (20%) participant preference, 2 (40%) medical decision; those in men were 3 (9%) virological failure, 13 (37%) potential TRAEs, 6 (17%) participant preference, 5 (14%) medical decision, and 8 (23%) changed location/other. No statistically significant differences by sex were noted. Besides ISRs, 46 (10%) participants reported TRAE by week 52, all grade 1–2, with no differences by sex. Patient-Reported Outcomes Electronic questionnaires were answered by 442 participants of 461 participants who reached 52 weeks of follow-up, 29 women and 412 men. When asked about their motivation to switch to LA-CAB/RPV, 57% of patients considered “it is a more comfortable treatment to integrate into my daily life” as their primary reason, with no significant differences between sexes (p = 0.414) (SM Fig. S1). Baseline responses from the treatment general acceptance dimension of ACCEPT questionnaire showed that a higher percentage of men, compared with women, totally agreed that “My medication has more advantages than disadvantages” (80% vs. 66%; p = 0.092) and that “Do you consider your medication an acceptable solution?” (86% vs. 79%; p = 0.138), although these differences did not reach statistical significance. From baseline to week 52, significant improvements (p < 0.001) were observed in the responses to these questions both in women and men, although when disaggregated by sex, only remained significant for men (SM Fig. S2). Tolerability of injections (VAS scale) (coefficient − 0.74, p < 0.001), perception of pain (RR 1.21, [95% CI 1.12–1.31], p < 0.001) and swelling after injections (RR 1.03, [95% CI 0.98–1.09], p = 0.001), significantly improved during follow-up, with no significant differences between women and men (SM Figs. S3 and S4). Global acceptability of pain significantly improved (RR 1.21, [95% CI 1.12–1.31], p < 0.001) while global acceptability of ISRs was high during all follow-up, without significant evolutive changes (RR 1.06, [95% CI 1.00–1.12], p = 0.103), with no significant differences between women and men (Fig. S5). At week 52, among participants who answered preference questionnaire (23 women and 311 men), 98% expressed a preference for LA-ART over their previous oral regimen (98% of men and 96% of women; p = 0.396). The most frequently cited reasons included greater convenience for daily life, dosing frequency, and decreased medication-related stress, without differences by sex. Aggregated score for quality of life domain of the HAT-QoL questionnaire remained stable in the global analysis during follow-up. However, when disaggregated by items and sex, women showed a statistically significant improvement in the “I’ve been satisfied with how socially active I am” question (69% to 87%, RR 1.26, [95% CI 1.03–1.55], p = 0.027) compared with no significant change in men (Fig. S6 and Tables S4 and S5). Aggregated score for the HIV medication burden domain improved globally during follow-up (86 to 91, p < 0.001). At baseline, more women than men reported that medication had been a burden (48% vs. 31%); however, the difference was not statistically significant (RR 0.75 [95% CI 0.52–1.07] p = 0.111). Moreover, a tendency for a greater improvement during follow-up was seen in women (RR 1.34 [95% CI 0.95–1.89] p = 0.098) and at week 52 only 10% of both women and men reported medication as a burden. Similar results were observed for the question “my medication has made it hard to live a normal life” (Fig. S7 and Tables S6 and S7). Aggregated score for the disclosure worries domain in women was low at baseline (47) and did not improve during follow-up (42 at week 52; coefficient for change − 6.51 [95% CI − 14.93 to 1.91] p = 0.129). Women had lower scores than men in all visits, with the difference being statistically significant in week 12 and 52. At baseline, women were more likely than men to report “limiting what they tell others about themselves” (38% vs. 12% answered “all of the time”, p = 0.002), “being afraid to disclose their HIV status” (62% vs. 31%, p = 0.007), and “worrying about losing their source of income if others found out they had HIV” (34% vs. 19%, p = 0.058). These differences persisted during follow-up and were statistically significant at almost every visit. Responses partially improved over time, although without statistical significance (Fig. 2 and Tables S8 and S9).Fig. 2Disclosure concerns domain of the HIV/AIDS-targeted quality of life (HAT-QoL) by sex at birth in people switching to LA-CAB/RPV Disclosure concerns domain of the HIV/AIDS-targeted quality of life (HAT-QoL) by sex at birth in people switching to LA-CAB/RPV Discussion In this real-world prospective cohort, we observed a lower proportion of women switching to LA-CAB/RPV than men (defined by sex at birth), compared with those remaining with other ARTs in our unit. Given that gender refers to social constructs, behaviors, and roles that a society attributes to women and men, while biological sex relates to anatomical, genetic, hormonal, and physiological characteristics determined by sex chromosomes, both variables could be involved in these findings. Logistical barriers for women coming more often to clinic visits, often related to a higher load of caregiving responsibilities and other gender related social factors, may have contributed to worse adherence in the past or influenced their current treatment choices. A higher percentage of past virological failure was observed in both groups of women and more historical mutations were observed in women that did not switch to LA-CAB/RPV compared to men, making them not eligible for this regimen. Poorer treatment tolerance due to physiological differences may have led to higher treatment discontinuation, increasing the risk of virological failure and emergence of resistances in women [25]. In addition, women were older and with a longer exposure to ART. Similar baseline characteristics by sex have been reported in other Spanish cohorts [8, 10]. On the other hand, we cannot exclude potential prescription biases [26]. The lack of safety and efficacy data on CAB/RPV use during pregnancy may have contributed to a lower prescription in women of childbearing potential. Although some reassuring safety data are emerging [27], efficacy data in pregnancy is still lacking and thus this drug combination is not recommended for treatment during pregnancy. Although women are underrepresented in both clinical trials and real-world cohorts, large cohorts and multisite qualitative studies in the USA show that women, particularly younger women, those with caregiving responsibilities, psychological distress related to adherence, or unstable housing, often prefer long-acting injectable ART (LAI-ART) over pills owing to its convenience, confidentiality, and reduced daily reminders of living with HIV. These findings highlight the need for gender-responsive, user-centered implementation strategies to ensure informed choice and equitable access to LAI-ART [28–30]. A higher percentage of women than men switched to LA-CAB/RPV with a detectable viral load. Although we cannot exclude that it may be a chance finding given the small number of women, it could reflect higher adherence challenges in the women included. A specific analysis of those participants to better characterize their baseline characteristics and clinical evolution would help gain further insight into this scenario. Similar effectiveness with LA-CAB/RPV was observed between women and men in our real-life setting, adding information on the scarce sex-disaggregated data available in previous studies. Two Spanish studies have also shown similar effectiveness between women and men [8, 10], even though women had more comorbidities and longer previous ART experience, in accordance with our results. VF rate observed in our study was slightly higher than that reported in other cohorts (1.7%) [4–6]; however, this is largely attributable to our more stringent definition of VF (HIV-RNA > 50 copies/mL), whereas most cohorts use a threshold of > 200 copies/mL and VF definitions differ considerably among observational cohort studies [31]. Considering CONSENSUS-LAI definitions [19], VF rate was as low as 0.6%. Only one participant developed high-level resistance to both NNRTIs and INSTIs, accounting for 1/3 (33%) of the VF by CONSENSUS definitions. Another three participants with low-level viremias showed mutations in both NNRTI and INSTI by ultra-deep sequencing of HIV-1 DNA, but most of the mutations detected could be APOBEC-induced and of uncertain clinical impact. Importantly, many of the individuals classified as VF in our study did not require treatment modification and subsequently achieved undetectable VLs, suggesting that these episodes may reflect transient viremia rather than true failure. Discontinuations were more frequent among women due to adverse events and medical decision, although not statistically significant probably as a result of the small sample of women. A higher discontinuation rate of LA-CAB/RPV and more frequently due to general adverse effects in women compared with men have been previously observed [10]. Reporting adverse effects by sex is essential, since women have historically shown worse tolerability to ART, partly as a result of pharmacokinetic differences depending on biological sex [32, 33]. Poor tolerability is associated with lower adherence, compromising treatment efficacy [11, 34]. According to PROs, baseline treatment acceptance was high, although lower in women, and significantly improved during follow-up. Tolerability of injections, and perception of pain also improved during follow-up, in accordance with previous studies [2, 12, 13]. In previous qualitative studies, participants highlight the convenience and emotional benefits of LA therapy [35–37]. However no significant changes in validated quality of life questionnaires like the 12-Item Short Form Health Survey (SF-12) have been observed in clinical trials, underscoring challenges in capturing these dimensions [2, 12, 13]. HAT-QoL questionnaire, which was developed specifically for evaluating several domains of the quality of life in the context of HIV, may be a more reliable and useful tool for capturing emotional challenges in this scenario. In our series, although no global changes for the quality of life domain were noted during follow-up, women reported improvements in the “social satisfaction” area and HIV medication burden domain. Other studies have shown improvements in treatment satisfaction when switching to LA-CAB/RPV, using the HIV Treatment Satisfaction Questionnaire (HIVTSQ) [12, 14]. However, the HIV medication burden domain HAT-QoL questionnaire assesses more specifically the impact of ART in quality of life. Interestingly enough, women reported medication as a burden more frequently than men did at baseline and showed a greater improvement during follow-up, although the difference did not reach statistical significance, probably as a result of the small sample of women. Moreover, women expressed more disclosure worries than men at every visit, reflecting that women may face challenges related to HIV and stigma more frequently than men. However, the small sample of women included may limit the generalizability of the results, and we cannot exclude that differences in baseline characteristics by sex may have influenced the results. This study has several strengths. As a single-center study, follow-up and data collection were consistently and homogeneously captured, and we were able to compare baseline characteristics with those from the general cohort under routine follow-up. We included all people switching to LA-CAB/RPV, without excluding those who did not meet strict eligibility criteria according to the product label, thereby reflecting truly real-world experience. Furthermore, the inclusion of PROs measures allowed us to capture patient perspectives in real clinical practice. However, some limitations must be acknowledged. The small number of women included limits the ability to detect sex-based outcomes, and we cannot exclude that some clinically relevant differences were missed. Additionally, women baseline characteristics may have influenced the observed differences in PROs, and we cannot attribute our findings to a single factor. Moreover, as women differ from men not only among those switching to LA-CAB/RPV but also across the overall cohort at our center, the results likely reflect a complex interaction of clinical, demographic, and social factors rather than a single determinant. Additionally, the observational design of the study precludes causal inference and may be affected by selection and other biases. The single-center design may limit the generalizability of our findings to other contexts, although the results are consistent with previously published real-world cohorts and clinical trial data. These results warrant confirmation in larger studies with greater representation of women. Conclusions The efficacy and tolerability of LA-CAB/RPV were high and similar between women and men. In our study, women experienced a greater medication burden and more disclosure-related challenges than men, suggesting they might have a greater benefit from LA-ART. Nevertheless, a proportionally smaller number of women transitioned to this regimen. While some baseline characteristics associated with both gender and sex may partially account for this observation, the possibility of prescription bias or other gender-related factors cannot be excluded. Our findings highlight the importance of sex-disaggregated data in understanding the differential characteristics, needs, and concerns of people with HIV. Tailoring treatment strategies to address these differences is essential to ensure equitable and effective care. Supplementary Information Below is the link to the electronic supplementary material.Supplementary file1 (PDF 1100 KB) Supplementary file1 (PDF 1100 KB)